These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 22225786

  • 1. Stromal micropapillary component as a novel unfavorable prognostic factor of lung adenocarcinoma.
    Ohe M, Yokose T, Sakuma Y, Miyagi Y, Okamoto N, Osanai S, Hasegawa C, Nakayama H, Kameda Y, Yamada K, Isobe T.
    Diagn Pathol; 2012 Jan 06; 7():3. PubMed ID: 22225786
    [Abstract] [Full Text] [Related]

  • 2. Pulmonary adenocarcinoma with a micropapillary pattern: a clinicopathological, immunophenotypic and molecular analysis.
    Zhang J, Liang Z, Gao J, Luo Y, Liu T.
    Histopathology; 2011 Dec 06; 59(6):1204-14. PubMed ID: 22175900
    [Abstract] [Full Text] [Related]

  • 3. Stromal micropapillary pattern predominant lung adenocarcinoma--a report of two cases.
    Ohe M, Yokose T, Sakuma Y, Osanai S, Hasegawa C, Washimi K, Nawa K, Woo T, Hamanaka R, Nakayama H, Kameda Y, Yamada K, Isobe T.
    Diagn Pathol; 2011 Sep 29; 6():92. PubMed ID: 21955603
    [Abstract] [Full Text] [Related]

  • 4. High-grade lung adenocarcinomas with micropapillary and/or solid patterns: a review.
    Morales-Oyarvide V, Mino-Kenudson M.
    Curr Opin Pulm Med; 2014 Jul 29; 20(4):317-23. PubMed ID: 24852329
    [Abstract] [Full Text] [Related]

  • 5. [Pulmonary adenocarcinoma with micropapillary pattern: a clinicopathologic and immunohistochemical study].
    Zhang J, Liang ZY, Luo YF, Wan JW, Cao JL, Liu TH.
    Zhonghua Bing Li Xue Za Zhi; 2009 Oct 29; 38(10):651-6. PubMed ID: 20078967
    [Abstract] [Full Text] [Related]

  • 6. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.
    Russell PA, Barnett SA, Walkiewicz M, Wainer Z, Conron M, Wright GM, Gooi J, Knight S, Wynne R, Liew D, John T.
    J Thorac Oncol; 2013 Apr 29; 8(4):461-8. PubMed ID: 23486266
    [Abstract] [Full Text] [Related]

  • 7. Histopathological features and prognostic significance of the micropapillary pattern in lung adenocarcinoma.
    Kamiya K, Hayashi Y, Douguchi J, Hashiguchi A, Yamada T, Izumi Y, Watanabe M, Kawamura M, Horinouchi H, Shimada N, Kobayashi K, Sakamoto M.
    Mod Pathol; 2008 Aug 29; 21(8):992-1001. PubMed ID: 18516041
    [Abstract] [Full Text] [Related]

  • 8. Pulmonary adenocarcinomas with micropapillary component significantly correlate with recurrence, but can be well controlled with EGFR tyrosine kinase inhibitors in the early stages.
    Sumiyoshi S, Yoshizawa A, Sonobe M, Kobayashi M, Fujimoto M, Tsuruyama T, Date H, Haga H.
    Lung Cancer; 2013 Jul 29; 81(1):53-9. PubMed ID: 23632273
    [Abstract] [Full Text] [Related]

  • 9. [To evaluate the clinicopathologic characteristics and outcome of tumor cells spreading through air spaces in patients with adenocarcinoma of lung].
    Sun PL, Liu JN, Cao LQ, Yao M, Gao HW.
    Zhonghua Bing Li Xue Za Zhi; 2017 May 08; 46(5):303-308. PubMed ID: 28468034
    [Abstract] [Full Text] [Related]

  • 10. Association of c-Met phosphorylation with micropapillary pattern and small cluster invasion in pT1-size lung adenocarcinoma.
    Koga K, Hamasaki M, Kato F, Aoki M, Hayashi H, Iwasaki A, Kataoka H, Nabeshima K.
    Lung Cancer; 2013 Dec 08; 82(3):413-9. PubMed ID: 24094902
    [Abstract] [Full Text] [Related]

  • 11. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.
    Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F, Tsuruyama T, Travis WD, Date H, Haga H.
    J Thorac Oncol; 2013 Jan 08; 8(1):52-61. PubMed ID: 23242438
    [Abstract] [Full Text] [Related]

  • 12. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
    de Melo AC, Karen de Sá V, Sternberg C, Olivieri ER, Werneck da Cunha I, Fabro AT, Carraro DM, de Barros e Silva MJ, Pimenta Inada HK, de Mello ES, Soares FA, Takagaki T, Ferreira CG, Capelozzi VL.
    Oncology; 2015 Jan 08; 89(3):175-86. PubMed ID: 25833149
    [Abstract] [Full Text] [Related]

  • 13. A micropapillary pattern is predictive of a poor prognosis in lung adenocarcinoma, and reduced surfactant apoprotein A expression in the micropapillary pattern is an excellent indicator of a poor prognosis.
    Tsutsumida H, Nomoto M, Goto M, Kitajima S, Kubota I, Hirotsu Y, Wakimoto J, Hollingsworth MA, Yonezawa S.
    Mod Pathol; 2007 Jun 08; 20(6):638-47. PubMed ID: 17431413
    [Abstract] [Full Text] [Related]

  • 14. MET gene copy number gain is an independent poor prognostic marker in Korean stage I lung adenocarcinomas.
    Jin Y, Sun PL, Kim H, Seo AN, Jheon S, Lee CT, Chung JH.
    Ann Surg Oncol; 2014 Feb 08; 21(2):621-8. PubMed ID: 24212721
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
    Liu B, Shi SS, Wang X, Xu Y, Zhang XH, Yu B, Lu ZF, Wang JD, Zhou XJ.
    Zhonghua Bing Li Xue Za Zhi; 2012 Aug 08; 41(8):505-10. PubMed ID: 23157740
    [Abstract] [Full Text] [Related]

  • 17. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
    Qu Y, Che N, Zhao D, Zhang C, Su D, Zhou L, Zhang L, Wang C, Zhang H, Wei L.
    Tumour Biol; 2015 Aug 08; 36(8):6417-24. PubMed ID: 25813151
    [Abstract] [Full Text] [Related]

  • 18. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
    Kadota K, Sima CS, Arcila ME, Hedvat C, Kris MG, Jones DR, Adusumilli PS, Travis WD.
    Am J Surg Pathol; 2016 Dec 08; 40(12):1579-1590. PubMed ID: 27740967
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.